Evidence map›Paper›PMID 36551667›Full record

ArticleCancers2022

Multimodal Lung Cancer Subtyping Using Deep Learning Neural Networks on Whole Slide Tissue Images and MALDI MSI.

Charlotte Janßen, Tobias Boskamp, Jean Le'Clerc Arrastia, Daniel Otero Baguer, Lena Hauberg-Lotte, Mark Kriegsmann, Katharina Kriegsmann, Georg Steinbuß, Rita Casadonte, Jörg Kriegsmann and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Current trends and future directions of artificial intelligence in lung cancer diagnosis.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026
    Article
  2. [Spatial omics in pulmonary fibrosis: advancing mechanistic insights and therapeutic strategies].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Charlotte JanßenCenter for Industrial Mathematics (ZeTeM), University of Bremen, 28359 Bremen, Germany.ORCID 0000-0003-2121-9733
Tobias BoskampCenter for Industrial Mathematics (ZeTeM), University of Bremen, 28359 Bremen, Germany.ORCID 0000-0002-5233-7962
Jean Le'Clerc ArrastiaCenter for Industrial Mathematics (ZeTeM), University of Bremen, 28359 Bremen, Germany.ORCID 0000-0002-1123-6110
Daniel Otero BaguerCenter for Industrial Mathematics (ZeTeM), University of Bremen, 28359 Bremen, Germany.ORCID 0000-0001-6550-6043
Lena Hauberg-LotteCenter for Industrial Mathematics (ZeTeM), University of Bremen, 28359 Bremen, Germany.
Mark KriegsmannInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-7319-3646
Katharina KriegsmannDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Georg SteinbußDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Rita CasadonteProteopath, 54926 Trier, Germany.ORCID 0000-0002-9054-4786
Jörg KriegsmannProteopath, 54926 Trier, Germany.
Peter MaaßCenter for Industrial Mathematics (ZeTeM), University of Bremen, 28359 Bremen, Germany.ORCID 0000-0003-1448-8345
University of Bremen · DEHeidelberg University · DEDanube Private University · AT

Funding

Federal Ministry of Education and Research FKZ 031L0198A
6 · The paper itself

Abstract

Artificial intelligence (AI) has shown potential for facilitating the detection and classification of tumors. In patients with non-small cell lung cancer, distinguishing between the most common subtypes, adenocarcinoma (ADC) and squamous cell carcinoma (SqCC), is crucial for the development of an effective treatment plan. This task, however, may still present challenges in clinical routine. We propose a two-modality, AI-based classification algorithm to detect and subtype tumor areas, which combines information from matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) data and digital microscopy whole slide images (WSIs) of lung tissue sections. The method consists of first detecting areas with high tumor cell content by performing a segmentation of the hematoxylin and eosin-stained (H&E-stained) WSIs, and subsequently classifying the tumor areas based on the corresponding MALDI MSI data. We trained the algorithm on six tissue microarrays (TMAs) with tumor samples from N = 232 patients and used 14 additional whole sections for validation and model selection. Classification accuracy was evaluated on a test dataset with another 16 whole sections. The algorithm accurately detected and classified tumor areas, yielding a test accuracy of 94.7% on spectrum level, and correctly classified 15 of 16 test sections. When an additional quality control criterion was introduced, a 100% test accuracy was achieved on sections that passed the quality control (14 of 16). The presented method provides a step further towards the inclusion of AI and MALDI MSI data into clinical routine and has the potential to reduce the pathologist's work load. A careful analysis of the results revealed specific challenges to be considered when training neural networks on data from lung cancer tissue.

Indexed as

artificial intelligencedeep learninglung cancermass spectrometry imagingnon-small cell lung cancertumor detectiontumor segmentationwhole slide images

Identifiers

PMID36551667
PMCPMC9776684
OpenAlexW4311789553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.